Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Korean Participants With Osteoarthritis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-03-14
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 239
- Registration Number
- NCT01554163
A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223)
Phase 2
Completed
- Conditions
- Interventions
- Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcgDrug: Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcgDrug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcgDrug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcgDrug: Placebo Dry Powder Inhaler (DPI)Drug: Placebo Metered Dose Inhaler (MDI)
- First Posted Date
- 2011-12-30
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 583
- Registration Number
- NCT01502371
An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 42
- Registration Number
- NCT01498770
Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307)
Completed
- Conditions
- First Posted Date
- 2011-12-20
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 42
- Registration Number
- NCT01495741
Study of the Use of a Contraceptive Vaginal Ring (NuvaRing) in Normal Daily Practice in Indian Women (P07733)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 252
- Registration Number
- NCT01490190
A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 11744
- Registration Number
- NCT01471340
Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1)
- First Posted Date
- 2011-10-31
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 139
- Registration Number
- NCT01462370
Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-09-20
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 200
- Registration Number
- NCT01437111
Study of Lipid Control in Hyperlipidemic Participants (MK-0653-179)
- First Posted Date
- 2011-09-19
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 2196
- Registration Number
- NCT01436253
A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3)
- First Posted Date
- 2011-09-09
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 15
- Registration Number
- NCT01431508
© Copyright 2024. All Rights Reserved by MedPath